Moderna Inc. and Vertex Pharmaceuticals Incorporated announced a new strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles and mRNAs for the delivery of gene-editing therapies for the treatment of cystic fibrosis (CF).
Strand Therapeutics is genetically programming RNA not just to deliver a gene of interest, but to control the location, timing and intensity of therapeutic protein expression using mRNA-encoded logic circuits.
Tianjin, China’s CanSino Biologics entered into a co-development agreement with Vancouver, British Columbia’s Precision NanoSystems for an mRNA lipid nanoparticle vaccine against COVID-19.
The software of life is how Moderna Inc. CEO Stephane Bancel describes messenger RNA (mRNA), which is at the core of the company’s drug development process.
Cambridge, Mass.-based Dicerna Pharmaceuticals signed a research collaboration and licensing deal with Switzerland’s Roche for chronic hepatitis B virus therapies that could hit $1.67 billion.
Cambridge, Mass.-based bluebird bio and Bagsvaerd, Denmark-based Novo Nordisk agreed to develop next-generation genome editing therapies for genetic diseases, including hemophilia.
Anima Biotech technology uses state-of-the-art molecular biology that can illuminate the protein synthesis process and identify small molecules that regulate mRNA translation.
Researchers may have found a solution to treating a bone marrow cancer proven to be resistant to several standard therapies.
Tubingen, Germany-based CureVac entered a collaboration research agreement with Yale University to focus on lung therapies.
Arcturus Surges Ahead in the mRNA Market, Regaining 100% Rights to OTC Deficiency Therapy
Collaboration, Cystic Fibrosis, Genetics, Infants, Investigational New Drug (IND) applications, Liver Cells, Messenger RNA (mRNA) Therapeutics, OTC deficiency, OTC enzymes, OTC gene, Product Pipelines, Respiratory Syncytial Virus, USPTO, VaccinationsSan Diego-based Arcturus Therapeutics Ltd. announced that the company was reassuming 100 percent of its global rights from Germany-based CureVac AG for ARCT-810, a messenger RNA (mRNA) drug to treat OTC deficiency.